Artivion, Inc. (AORT)
NYSE: AORT · Real-Time Price · USD
36.91
+0.34 (0.94%)
Apr 22, 2026, 2:20 PM EDT - Market open
Artivion Revenue
In the year 2025, Artivion had annual revenue of $441.33M with 13.59% growth. Artivion had revenue of $115.99M in the quarter ending December 31, 2025, with 19.20% growth.
Revenue (ttm)
$441.33M
Revenue Growth
+13.59%
P/S Ratio
4.13
Revenue / Employee
$245,183
Employees
1,800
Market Cap
1.79B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 441.33M | 52.79M | 13.59% |
| Dec 31, 2024 | 388.54M | 34.53M | 9.75% |
| Dec 31, 2023 | 354.00M | 40.22M | 12.82% |
| Dec 31, 2022 | 313.79M | 14.95M | 5.00% |
| Dec 31, 2021 | 298.84M | 45.61M | 18.01% |
| Dec 31, 2020 | 253.23M | -23.00M | -8.32% |
| Dec 31, 2019 | 276.22M | 13.38M | 5.09% |
| Dec 31, 2018 | 262.84M | 73.14M | 38.55% |
| Dec 31, 2017 | 189.70M | 9.32M | 5.17% |
| Dec 31, 2016 | 180.38M | 34.48M | 23.63% |
| Dec 31, 2015 | 145.90M | 1.26M | 0.87% |
| Dec 31, 2014 | 144.64M | 3.88M | 2.75% |
| Dec 31, 2013 | 140.76M | 9.05M | 6.87% |
| Dec 31, 2012 | 131.72M | 12.09M | 10.11% |
| Dec 31, 2011 | 119.63M | 2.98M | 2.56% |
| Dec 31, 2010 | 116.65M | 4.96M | 4.44% |
| Dec 31, 2009 | 111.69M | 6.63M | 6.31% |
| Dec 31, 2008 | 105.06M | 10.30M | 10.87% |
| Dec 31, 2007 | 94.76M | 13.45M | 16.54% |
| Dec 31, 2006 | 81.31M | 12.03M | 17.36% |
| Dec 31, 2005 | 69.28M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AdaptHealth | 3.24B |
| Tandem Diabetes Care | 1.01B |
| Inspire Medical Systems | 911.98M |
| Neogen | 870.56M |
| Alphatec Holdings | 764.16M |
| NovoCure | 655.35M |
| UFP Technologies | 602.80M |
| PROCEPT BioRobotics | 308.05M |
AORT News
- 15 days ago - Artivion Announces U.S. FDA Approval of the NEXUS® Aortic Arch System - PRNewsWire
- 7 weeks ago - Artivion to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference - PRNewsWire
- 2 months ago - Artivion Reports Fourth Quarter and Full Year 2025 Financial Results - PRNewsWire
- 2 months ago - Artivion Announces Presentation of Positive New Clinical Data from NEXUS TRIOMPHE and AMDS PERSEVERE Trials at the 62nd Society of Thoracic Surgery Annual Meeting - PRNewsWire
- 2 months ago - Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter 2025 Financial Results - PRNewsWire
- 5 months ago - Artivion Reports Third Quarter 2025 Financial Results - PRNewsWire
- 5 months ago - Artivion Announces Treatment of First Patient with Arcevo LSA in ARTIZEN Pivotal Trial - PRNewsWire
- 6 months ago - Artivion to Participate in the Stifel 2025 Healthcare Conference - PRNewsWire